Hawthorn executes deal with university
MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.
Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.
“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.
“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”
To sign up for Mississippi Business Daily Updates, click here.
Top Posts & Pages
- (UPDATE) Prison won’t interrupt ex-prison chief’s retirement cash flow
- 2014 a good year for filmmaking in Mississippi
- JOSH MABUS — Inbound marketing is fueled by wishful thinking
- MARTIN WILLOUGHBY — Doug Dale’s self-awareness helps lift him to top of his game
- PHIL HARDWICK: When Bill Cooley talks, people listen
- Ex-prison boss and businessman admit to bribery scheme
- MBJ Business Woman of the Year Top 10
- ASA postmortem: industrial recruiting is a constant cycle of death and life
- Kemper plant employee gag order continued